Clinical relevance of colorectal cancer molecular subtypes

Critical Reviews in Oncology/Hematology

Volumn 109, Issue , 2017, Pages 9-19

  Rodriguez Salas, Nuria ^a   Dominguez, Gema ^b   Barderas, Rodrigo ^c   Mendiola, Marta ^a   García Albéniz, Xabier ^d   Maurel, Juan ^e   Batlle, Jaime Feliu ^a,f  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF BARCELONA   (Spain)

^f INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Colorectal cancer; Molecular subtypes; Personalized treatment

Indexed keywords

ANTINEOPLASTIC AGENT; APC PROTEIN; AURORA KINASE INHIBITOR; B RAF KINASE; BIBRANIV; CEDIRANIB; CETUXIMAB; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; GLYCOGEN SYNTHASE KINASE INHIBITOR; GLYCOLYSIS INHIBITOR; IRINOTECAN; MONOCLONAL ANTIBODY; MYC PROTEIN; N BENZYL 1,2,3,4,8,9 HEXAHYDRO 6 (4 HYDROXYBENZYL) 8 (1 NAPHTHYLMETHYL) 4,7 DIOXO 2H PYRAZINO[1,2 A]PYRIMIDINE 1(6H) CARBOXAMIDE; OXALIPLATIN; PAZOPANIB; PEMBROLIZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PLERIXAFOR; PROTEIN P53; PYRUVATE DEHYDROGENASE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TELATINIB; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; WNT PROTEIN;

APC GENE; BRAF GENE; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER PROGNOSIS; COLORECTAL CANCER; CTNNB GENE; DRUG INDICATION; GENE; GENE AMPLIFICATION; GENE INACTIVATION; GENE MUTATION; HUMAN; KRAS GENE; NONHUMAN; ONCOGENE MYC; PHENOTYPE; PI3CA GENE; REVIEW; TP53 GENE; TRANSFORMING GROWTH FACTOR BETA GENE; WNT SIGNALING PATHWAY; ANIMAL; CLASSIFICATION; COLORECTAL NEOPLASMS; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PERSONALIZED MEDICINE; PROGNOSIS; SIGNAL TRANSDUCTION;

ANIMALS; COLORECTAL NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; PRECISION MEDICINE; PROGNOSIS; SIGNAL TRANSDUCTION;

EID: 85006511881     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2016.11.007     Document Type: Review

References (92)

1. André, T., de Gramont, A., Vernerey, D., Chibaudel, B., Bonnetain, F., Tijeras-Raballand, A., et al. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J. Clin. Oncol. 33 (2015), 4176–4187.
2. Arnold, M., Karim-Kos, H.E., Coebergh, J.W., Byrnes, G., Antilla, A., Ferlay, J., Renehan, A.G., Forman, D., Soerjomataram, I., Recent trends in incidence of five common cancers in 26 European countries since 1988. Anal. Eur. Cancer Obs. Eur. J. Cancer 51:June (9) (2015), 1164–1187.
3. Babaei-Jadidi, R., Li, N., Saadeddin, A., et al. FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation. J. Exp. Med. 208 (2011), 295–312.
4. Baker, S.J., Fearon, E.R., Nigro, J.M., et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244 (1989), 217–221.
5. Barbie, D.A., Tamay o, P., Boehm, J.S., et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462 (2009), 108–112.
6. Bardi, G., Fenger, C., Johansson, B., et al. Tumor kary oty pe predicts clinical outcome in colorectal cancer patients. J. Clin. Oncol. 22 (2004), 2623–2634.
7. Becht, E., de Reynie, A., Giraldo, N.A., et al. Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy. Clin. Cancer Res. 22:16 (2016), 4057–4066.
8. Bertagnolli, M.M., Niedzwiecki, D., Compton, C.C., et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: cancer and Leukemia Group B Protocol 89803. J. Clin. Oncol. 27 (2009), 1814–1821.
9. Bos, J.L., Fearon, E.R., Hamilton, S.R., et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 327 (1987), 293–297.
10. Calon, A., Lonardo, E., Berenguer-Llergo, A., Espinet, E., Hernando-Momblona, X., Iglesias, M., et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat. Genet. 47 (2015), 320–329.
11. Cancer Genome Atlas Network, Comprehensive molecular characterization of human colon and rectal cancer. Nature 487 (2012), 330–337.
12. Chen, J., Elfiky, A., Han, M., Chen, C., Saif, M.W., The role of Src in colon cancer and its therapeutic implications. Clin. Colorectal Cancer 13 (2014), 5–13.
13. Corcoran, R.B., Ebi, H., Turke, A.B., et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2 (2012), 227–235.
14. Custodio, A., Barriuso, J., de Castro, J., Martínez-Marín, V., Moreno, V., Rodríguez-Salas, N., Feliu, J., Molecular markers to predict outcome to antiangiogenic therapies in colorectal cancer: current evidence and future perspectives. Cancer Treat. Rev. 39:8 (2013), 908–924.
15. Dalerba, Piero, Sahoo, Debashis, Paik, Soonmyung, et al. CDX2 as a prognostic biomarker in stage II and stage III colon cancer. N. Eng. J. Med. 374:3 (2016), 211–222.
16. De Smedt, L., Lemahieu, J., Palmans, S., et al. Microsatellite instable vs stable colon carcinomas: analysis of tumour heterogeneity, inflammation and angiogenesis. Br. J. Cancer 113:3 (2015), 500–509.
17. De Sousa E Melo, F., Wang, X., Jansen, M., Fessler, E., Trinh, A., de Rooij, L.P.M.H., et al. Poor-prognosis colon cancer is defined by a moleculary distinct subtype and develops from serrated precursors lesions. Nat. Med. 19 (2013), 614–621.
18. Di Nicolantonio, F., Martini, M., Molinari, F., et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 26 (2008), 5705–5712.
19. Dienstmann, R., Salazar, R., Tabernero, J., Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients. J. Clin. Oncol. 33 (2015), 1787–1796.
20. Domínguez, G., García, J.M., Peña, C., Silva, J., García, V., Martínez, L., Maximiano, C., Gómez, M.E., Rivera, J.A., García-Andrade, C., Bonilla, F., DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1. J. Clin. Oncol. 24:February (5) (2006), 805–815.
21. Downward, J., Targeting RAS signalling pathway s in cancer therapy. Nat. Rev. Cancer 3 (2003), 11–22.
22. Ebi, H., Corcoran, R.B., Singh, A., et al. Receptor ty rosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J. Clin. Invest. 121 (2011), 4311–4321.
23. Fallik, D., Borrini, F., Boige, V., Viguier, J., Jacob, S., Miquel, C., et al. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cáncer. Cancer Res. 63 (2003), 5738–5744.
24. Feinberg, A.P., Gehrke, C.W., Kuo, K.C., et al. Reduced genomic 5-methy lcy tosine content in human colonic neoplasia. Cancer Res. 48 (1988), 1159–1161.
25. Feng, Y., Bommer, G.T., Zhao, J., et al. Mutant KRAS promotes hy perplasia and alters differentiation in the colon epithelium but does not expand the presumptive stem cell pool. Gastroenterology 141 (2011), 1003–1013 e1–e10.
26. Firestein, R., Bass, A.J., Kim, S.Y., et al. CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature 455 (2008), 547–551.
27. Flaherty, K.T., Puzanov, I., Kim, K.B., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363 (2010), 809–819.
28. Galon, J., Mlecnik, B., Bindea, G., et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J. Pathol. 232 (2014), 199–209.
29. Galon, J., Mlecnik, B., Marliot, F., et al. Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: results of a worldwide consortium-based analysis of 1,336 patients. J. Clin. Oncol., vol. 34(15_suppl. (May 20 Suppl.)), 2016, 3500 2016 ASCO Annual Meeting (June 3–7, 2016).
30. Garraway, L.A., Concordance and discordance in tumor genomic profiling. J. Clin. Oncol. 30 (2012), 2937–2939.
31. Gavin, P.G., Colangelo, L.H., Fumagalli, D., et al. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin. Cancer Res. 18 (2012), 6531–6541.
32. Goelz, S.E., Vogelstein, B., Hamilton, S.R., et al. Hypomethy lation of DNA from benign and malignant human colon neoplasms. Science 228 (1985), 187–190.
33. Guinney, J., Dienstmann, R., Wang, X., et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 21 (2015), 1350–1356.
34. Gupta, S., Ramjaun, A.R., Haiko, P., et al. Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 129 (2007), 957–968.
35. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
36. Holleczek, B.1, Rossi, S.2, Domenic, A.3, Innos, K.4, Minicozzi, P.5, Francisci, S.2, Hackl, M.6, Eisemann, N.7, Brenner H8 EUROCARE-5 working group. On-going improvement and persistent differences in the survival for patients with colon and rectum cancer across Europe 1999–2007 – results from the EUROCARE-5 study. Eur. J. Cancer, 2015 pii: S0959-8049(15)00704-2.
37. Howe, J.R., Roth, S., Ringold, J.C., et al. Mutations in the SMAD4/DPC4 gene in juvenile poly posis. Science 280 (1998), 1086–1088.
38. Ionov, Y., Peinado, M.A., Malkhosy an, S., et al. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363 (1993), 558–561.
39. Isella, C., Terrasi, A., Bellomo, S.E., Petti, C., Galatola, G., Muratore, A., et al. Stromal contribution to the colorectal cancer transcriptome. Nat. Genet. 47 (2015), 312–319.
40. Jayson, G.C.1, Kerbel, R.2, Ellis, L.M.3, Harris, A.L.4, Antiangiogenic therapy in oncology: current status and future directions. Lancet, 2016 pii: S0140-6736(15)01088-0.
41. Klingbiel, D., Saridaki, Z., Roth, A.D., et al. Prognosis of stage II and III colon carcinoma treated with adjuvant 5-FU or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial. Ann. Oncol. 26 (2015), 126–132.
42. López-Gómez, M., Moreno-Rubio, J., Suárez-García, I., Cejas, P., Madero, R., Casado, E., et al. Gene expression differences in primary colorectal tumors and matched liver metastases: chemotherapy related or tumoral heterogeneity?. Clin. Transl. Oncol. 17 (2015), 322–329.
43. Le, D.T., Uram, J.N., Wang, H., Bartlett, B.R., et al. PD-1 blockage in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372 (2015), 2509–2520.
44. Leary, R.J., Lin, J.C., Cummins, J., et al. Integrated analy sis of homozy gous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 16224–16229.
45. Leggett, B., Whitehall, V., Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology 138 (2010), 2088–2100.
46. Lepourcelet, M., Chen, Y.N., France, D.S., et al. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell 5 (2004), 91–102.
47. Li, W., Zhu, T., Guan, K.L., Transformation potential of Ras isoforms correlates with activation of phosphatidy linositol 3-kinase but not ERK. J. Biol. Chem. 279 (2004), 37398–37406.
48. Malesci, A., Laghi, I., Bianchi, P., Delconte, G., Randolph, A., Torri, V., et al. Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer. Clin. Cancer Res. 13 (2007), 3831–3839.
49. Marisa, L., de Reynies, A., Duval, A., et al. Gene expression classification of colon cáncer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med., 10, 2013, e1001453.
50. Martin, E.S., Tonon, G., Sinha, R., et al. Common and distinct genomic events in sporadic colorectal cancer and diverse cancer ty pes. Cancer Res. 67 (2007), 10736–10743.
51. Mehlen, P., Fearon, E.R., Role of the dependence receptor DCC in colorectal cancer pathogenesis. J. Clin. Oncol. 22 (2004), 3420–3428.
52. Michael-Robinson, J.M., Biemer-Huttmann, A., Purdie, D.M., et al. Tumour infiltrating lymphocytes and apoptosis are independent features in colorectal cáncer stratified according to microsatellite instability status. Gut 48 (2001), 360–366.
53. Midgley, R.S., Tomlinson, I., Johnstone, E., et al. Final results from QUASAR2, a multicentre, international randomised phase III trial of capecitabine (CAP) +/− bevacizumab (BEV) in the adjuvant setting of stage II/III colorectal cancer (CRC). Ann. Oncol. 25:suppl. 5 (2014), v1–v41.
54. Ogino, S., Nosho, K., Irahara, N., et al. Prognostic significance and molecular associations of 18q loss of heterozy gosity: a cohort study of microsatellite stable colorectal cancers. J. Clin. Oncol. 27 (2009), 4591–4598.
55. Pino, M.S., Chung, D.C., The chromosomal instability pathway in colon cancer. Gastroenterology 138 (2010), 2059–2072.
56. Plass, C., Pfister, S.M., Lindroth, A.M., et al. Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat. Rev. Genet. 14 (2013), 765–780.
57. Pogue-Geile, K., Yothers, G., Taniyama, Y., et al. Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08. J. Natl. Cancer Inst. 105 (2013), 989–992.
58. Pogue-Geile, K.L., Song, N., Gavin, P.G., et al. Clinical outcome and benefit of oxaliplatin in colon cancer according to intrinsic subtypes: results from NRG Oncology/NSABP C-07. J. Clin. Oncol., 34, 2016 suppl; abstr 3510.
59. Pogue-Geile, K.L., Song, N., Gavin, P.G., et al. Clinical outcome and benefit of oxaliplatin in colon cancer according to intrinsic subtypes: results from NRG Oncology/NSABP C-07. J. Clin. Oncol., vol. 34(15_suppl (May 20 Suppl.)), 2016, 3510 2016 ASCO Annual Meeting (June 3–7, 2016).
60. Popat, S., Hubner, R., Houlston, R.S., Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol. 23 (2005), 609–618.
61. Prahallad, A., Sun, C., Huang, S., et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483 (2012), 100–103.
62. Pretlow, T.P., Aberrant cry pt foci and K-ras mutations: earliest recognized play ers or innocent by standers in colon carcinogenesis?. Gastroenterology 108 (1995), 600–603.
63. Rad, R., Cadinanos, J., Rad, L., et al. A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention. Cancer Cell 24 (2013), 15–29.
64. Ribic, C.M., Sargent, D.J., Moore, M.J., et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 349 (2003), 247–257.
65. Riggins, G.J., Kinzler, K.W., Vogelstein, B., Thiagalingam, S., Frequency of Smad gene mutations in human cancers. Cancer Res. 57 (1997), 2578–2580.
66. Roepman, P., Schlicker, A., Tabernero, J., et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int. J. Cancer 134 (2013), 552–562.
67. Ryan, D., Should FOLFOXIRI plus bevacizumab Be the standard first-Line therapy in metastatic colorectal cancer?. Oncologist 20:March (3) (2015), 236–238.
68. Sadanandam, A., Lyssiotis, C., Homicsko, K., Collisson, E.A., Gibb, W.J., Wullschleger, S., et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat. Med. 19 (2013), 619–625.
69. Sadanandam, A., Wang, X., De Sousa, E., Melo, F., Gray, J.W., Vermeulen, L., Hanahan, D., et al. Reconciliation of classification systems defining molecular subtypes of colorectal cancer: interrelationships and clinical implications. ABBV Cell Cycle 13 (2014), 353–357.
70. Salazar, R., Roepman, P., Capella, G., Moreno, V., Simon, I., Dreezen, C., et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J. Clin. Oncol. 29 (2011), 17–24.
71. Samuels, Y., Wang, Z., Bardelli, A., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science, 304, 2004, 554.
72. Sancho, R., Jandke, A., Davis, H., et al. F-box and WD repeat domain-containing 7 regulates intestinal cell lineage commitment and is a haploinsufficient tumor suppressor. Gastroenterology 139 (2010), 929–941.
73. Sanoff, H.K., Sargent, D.J., Campbell, M.E., et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: n9741. J. Clin. Oncol. 26 (2008), 5721–5727.
74. Sansom, O.J., Meniel, V., Wilkins, J.A., et al. Loss of Apc allows phenoty pic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 14122–14127.
75. Shaw, R.J., Cantley, L.C., Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441 (2006), 424–430.
76. Shiovitz, S., Bertagnolli, M.M., Renfro, L.A., et al. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. Gastroenterology 147 (2014), 637–645.
77. Shirasawa, S., Furuse, M., Yokoy ama, N., et al. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260 (1993), 85–88.
78. Simons, C.C., Hughes, L.A., Smits, K.M., Khalid-de Bakker, C.A., de Bruïne, A.P., Carvalho, B., et al. A novel classification of colorectal tumors based on microsatellite instability, the CpG island methylator phenotype and chromosomal instability: implications for prognosis. Ann. Oncol. 24 (2013), 2048–2056.
79. Sinicrope, F.A., Foster, N.R., Thibodeau, S.N., Marsoni, S., Monges, G., Labianca, R., et al. DNA mismatch repair status and colon cáncer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J. Natl. Cancer Inst. 103 (2011), 863–875.
80. Sjoblom, T., Jones, S., Wood, L.S., et al. The consensus coding sequences of human breast and colorectal cancers. Science 314 (2006), 268–274.
81. Soldevilla, B., Díaz, R., Silva, J., Campos-Martín, Y., Muñoz, C., García, V., García, J.M., Peña, C., Herrera, M., Rodriguez, M., Gómez, I., Mohamed, N., Marques, M.M., Bonilla, F., Domínguez, G., Prognostic impact of ΔTAp73 isoform levels and their target genes in colon cancer patients. Clin. Cancer Res. 17:September (18) (2011), 6029–6039, 10.1158/1078-0432. CCR-10-2388.
82. Souglakos, J., Philips, J., Wang, R., et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br. J. Cancer 101 (2009), 465–472.
83. Tanaka, H., Deng, G., Matsuzaki, K., et al. BRAF mutation, CpG island methy lator phenoty pe and microsatellite instability occur more frequently and concordantly in mucinous than non-mucinous colorectal cancer. Int. J. Cancer 118 (2006), 2765–2771.
84. Teng, F., Tian, W.Y., Wang, Y.M., Zhang, Y.F., Guo, F., Zhao, J., Gao, C., Xue, F.X., Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis. J Hematol. Oncol., 9(February (1)), 2016, 8.
85. Teufel, M., Schwenke, S., Seidel, H., Beckmann, G., Reischi, J., Vonk, R., et al. Molecular subtypes and outcomes in regorafenib-treated patients with metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial. J. Clin. Oncol., 33, 2015 abstr 3558.
86. Thiagalingam, S., Lengauer, C., Leach, F.S., et al. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat. Genet. 13 (1996), 343–346.
87. Vilar, E., Scaltriti, M., Balmana, J., Saura, C., Guzman, M., Arribas, J., et al. Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cáncer cell lines. Br. J. Cancer 99 (2008), 1607–1612.
88. Vogelstein, B., Fearon, E.R., Hamilton, S.R., et al. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319 (1988), 525–532.
89. Vogelstein, B., Fearon, E.R., Kern, S.E., et al. Alleloty pe of colorectal carcinomas. Science 244 (1989), 207–211.
90. Vogelstein, B., Papadopoulos, N., Velculescu, V.E., et al. Cancer genome landscapes. Science 339 (2013), 1546–1558.
91. Yang, A.D., Fan, F., Camp, E.R., van Buren, G., Liu, W., Somcio, R., et al. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin. Cancer Res. 12:July (14 Pt. 1) (2006), 4147–4153.
92. Yothers, G., O'Connell, M.J., LeeMet al.Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin. J. Clin. Oncol. 31 (2013), 4512–4519.